KR20200018652A - 타액에 멜라토닌을 가용화하는 산성화제를 포함하는 구강 용해 멜라토닌 제제 - Google Patents

타액에 멜라토닌을 가용화하는 산성화제를 포함하는 구강 용해 멜라토닌 제제 Download PDF

Info

Publication number
KR20200018652A
KR20200018652A KR1020207001344A KR20207001344A KR20200018652A KR 20200018652 A KR20200018652 A KR 20200018652A KR 1020207001344 A KR1020207001344 A KR 1020207001344A KR 20207001344 A KR20207001344 A KR 20207001344A KR 20200018652 A KR20200018652 A KR 20200018652A
Authority
KR
South Korea
Prior art keywords
formulation
saliva
composition
acid
disintegrant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020207001344A
Other languages
English (en)
Korean (ko)
Inventor
사이드 엠 샤
다니엘 하싼
프레드 하싼
패트릭 코르시노
Original Assignee
피지션즈 씰, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피지션즈 씰, 엘엘씨 filed Critical 피지션즈 씰, 엘엘씨
Publication of KR20200018652A publication Critical patent/KR20200018652A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207001344A 2017-06-20 2018-06-15 타액에 멜라토닌을 가용화하는 산성화제를 포함하는 구강 용해 멜라토닌 제제 Withdrawn KR20200018652A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522473P 2017-06-20 2017-06-20
US62/522,473 2017-06-20
PCT/US2018/037698 WO2018236678A1 (en) 2017-06-20 2018-06-15 Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Publications (1)

Publication Number Publication Date
KR20200018652A true KR20200018652A (ko) 2020-02-19

Family

ID=64656010

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207001344A Withdrawn KR20200018652A (ko) 2017-06-20 2018-06-15 타액에 멜라토닌을 가용화하는 산성화제를 포함하는 구강 용해 멜라토닌 제제

Country Status (13)

Country Link
US (4) US10500280B2 (cg-RX-API-DMAC7.html)
EP (1) EP3641759B1 (cg-RX-API-DMAC7.html)
JP (1) JP7297685B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200018652A (cg-RX-API-DMAC7.html)
CN (1) CN110913853A (cg-RX-API-DMAC7.html)
AU (1) AU2018289284A1 (cg-RX-API-DMAC7.html)
BR (2) BR122021012549B8 (cg-RX-API-DMAC7.html)
CA (1) CA3067822C (cg-RX-API-DMAC7.html)
ES (1) ES2979335T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019015733A (cg-RX-API-DMAC7.html)
RU (1) RU2020101742A (cg-RX-API-DMAC7.html)
SG (1) SG11201912172YA (cg-RX-API-DMAC7.html)
WO (1) WO2018236678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US10828254B2 (en) 2018-09-28 2020-11-10 Intelgenx Corp. Oral film formulation for modulating absorption profile
CN112426408B (zh) * 2020-12-08 2023-12-19 广州帝奇医药技术有限公司 一种褪黑素组合物及其制备工艺
US20240189331A1 (en) * 2021-02-12 2024-06-13 Intelgenx Corp. Novel tryptamine oral film formulation
EP4351525A1 (en) * 2021-06-09 2024-04-17 AGB-Pharma AB Melatonin formulation in solid dosage form
US12440472B2 (en) 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films
US12648905B2 (en) 2022-01-19 2026-06-09 Intelgenx Corp. Oral films with flavor entrapment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6730330B2 (en) 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
EP1696959A2 (en) 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin combination therapy for improving sleep quality
KR20070030178A (ko) 2004-02-17 2007-03-15 트랜스오랄 파마슈티칼스, 인코포레이티드 구강 점막을 가로지르는 수면제 전달용 조성물 및 이의사용 방법
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
WO2006037763A1 (en) * 2004-10-05 2006-04-13 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
CA2601969A1 (en) * 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
WO2007095716A1 (en) 2006-02-23 2007-08-30 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
IL175338A0 (en) * 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
US20080171085A1 (en) 2007-01-11 2008-07-17 Natrol, Inc. Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
US20100119601A1 (en) 2007-04-11 2010-05-13 Pharmaceutical Productions Inc. Melatonin tablet and methods of preparation and use
US20080260823A1 (en) 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
JP2010526053A (ja) * 2007-05-01 2010-07-29 シグモイド・ファーマ・リミテッド ニモジピン医薬組成物
KR100905027B1 (ko) 2007-10-03 2009-06-30 (주)씨엘팜 식용 필름
US20110092602A1 (en) * 2008-04-25 2011-04-21 Nitin Shivcharan Laddha Rapidly disintegrating oral compositions of tramadol
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US20120213855A1 (en) 2011-02-17 2012-08-23 Cima Labs Inc. Dosage forms for weakly ionizable compounds
US20120315337A1 (en) * 2011-06-07 2012-12-13 Shah Syed Multiparticulate 5-htp compositions and related methods
US20130052234A1 (en) 2011-08-25 2013-02-28 Purebrands LLC Edible strips
ES2457718B1 (es) * 2012-09-24 2015-04-16 Universidad De Granada Composición farmacéutica bucodispersable de melatonina
US20140303227A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
ES2880618T3 (es) 2015-03-02 2021-11-25 Medlab Clinical U S Inc Sistemas de suministro transmucosa y transdérmico
SG11201912172YA (en) * 2017-06-20 2020-01-30 Physicians Seal Llc Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

Also Published As

Publication number Publication date
WO2018236678A1 (en) 2018-12-27
US20200268886A1 (en) 2020-08-27
US11224658B2 (en) 2022-01-18
RU2020101742A (ru) 2021-07-20
AU2018289284A1 (en) 2020-01-16
US20180360967A1 (en) 2018-12-20
SG11201912172YA (en) 2020-01-30
US10960075B2 (en) 2021-03-30
US11224657B2 (en) 2022-01-18
CN110913853A (zh) 2020-03-24
US20200069803A1 (en) 2020-03-05
US20200268887A1 (en) 2020-08-27
BR122021012549B1 (pt) 2022-02-22
ES2979335T3 (es) 2024-09-25
BR122021012549B8 (pt) 2022-10-25
JP7297685B2 (ja) 2023-06-26
CA3067822A1 (en) 2018-12-27
BR112019027286A2 (pt) 2020-07-21
EP3641759B1 (en) 2024-04-03
BR112019027286B1 (pt) 2022-02-22
US10500280B2 (en) 2019-12-10
EP3641759A4 (en) 2021-03-24
JP2020524162A (ja) 2020-08-13
CA3067822C (en) 2022-08-30
MX2019015733A (es) 2020-02-20
EP3641759A1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
JP7297685B2 (ja) 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤
CZ20012566A3 (cs) Jednotková dávka a způsob přípravy jednotkové dávky pro slizniční podávání
US20070082048A1 (en) Sleep aid formulations
JP2013040175A (ja) 真夜中不眠症の治療のための固体組成物およびその治療方法
EP4076380B1 (en) Transmucosal therapeutic system containing agomelatine
US11185526B2 (en) Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
EP4076381B1 (en) Transmucosal therapeutic system containing agomelatine
Jaiswal Oral strip technology: A review
WO2022157563A1 (en) A pharmaceutical composition comprising lidocaine and melatonin
HK40019696A (en) Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
Nagpal et al. Patent innovations in fast dissolving/disintegrating dosage forms
HK40090941A (en) Transmucosal therapeutic system containing agomelatine
HK40110942A (en) Transmucosal therapeutic system containing agomelatine
CN107296798A (zh) 抗发红组合物
HK40082929B (en) Transmucosal therapeutic system containing agomelatine
HK40082929A (en) Transmucosal therapeutic system containing agomelatine
HK40082930B (en) Transmucosal therapeutic system containing agomelatine
HK40082930A (en) Transmucosal therapeutic system containing agomelatine

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200115

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination